{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,29]],"date-time":"2026-10-29T21:31:43Z","timestamp":1793309503585,"version":"4.5.0"},"reference-count":15,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2026,9,1]],"date-time":"2026-09-01T00:00:00Z","timestamp":1788220800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2026,9,1]],"date-time":"2026-09-01T00:00:00Z","timestamp":1788220800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2026,9,1]],"date-time":"2026-09-01T00:00:00Z","timestamp":1788220800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-017"},{"start":{"date-parts":[[2026,9,1]],"date-time":"2026-09-01T00:00:00Z","timestamp":1788220800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-037"},{"start":{"date-parts":[[2026,9,1]],"date-time":"2026-09-01T00:00:00Z","timestamp":1788220800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-012"},{"start":{"date-parts":[[2026,9,1]],"date-time":"2026-09-01T00:00:00Z","timestamp":1788220800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-029"},{"start":{"date-parts":[[2026,9,1]],"date-time":"2026-09-01T00:00:00Z","timestamp":1788220800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-004"}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","theclinics.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Clinics in Dermatology"],"published-print":{"date-parts":[[2026,9]]},"DOI":"10.1016\/j.clindermatol.2026.09.011","type":"journal-article","created":{"date-parts":[[2026,9,16]],"date-time":"2026-09-16T14:59:26Z","timestamp":1789570766000},"update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":2,"title":["From Gila monster venom to dermatology: The history of glucagon-like peptide-1 receptor agonists"],"prefix":"10.1016","author":[{"given":"Sarah","family":"Dyson","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Leonard","family":"Hoenig","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nick J.","family":"Levell","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.clindermatol.2026.09.011_bib0001","unstructured":"World Health Organization. Obesity and overweight. Available at: https:\/\/www.who.int\/news-room\/fact-sheets\/detail\/obesity-and-overweight. Accessed June 10, 2026."},{"key":"10.1016\/j.clindermatol.2026.09.011_bib0002","first-page":"42","article-title":"A review of glucagon-like peptide-1 in dermatology","volume":"18","author":"Patino","year":"2025","journal-title":"J Clin Aesthet Dermatol"},{"key":"10.1016\/j.clindermatol.2026.09.011_bib0003","doi-asserted-by":"crossref","first-page":"589","DOI":"10.5479\/si.00963801.14-882.589","article-title":"A critical review of the characters and variations of the snakes of North America","volume":"14","author":"Cope","year":"1892","journal-title":"Proc US Natl Mus"},{"key":"10.1016\/j.clindermatol.2026.09.011_bib0004","unstructured":"The Tony Hillerman Portal, University of New Mexico. Cultural Reference. Available at: https:\/\/ehillerman.unm.edu\/taxonomy\/term\/172?page=40. Accessed June 10, 2026."},{"key":"10.1016\/j.clindermatol.2026.09.011_bib0005","unstructured":"The Tony Hillerman Portal, University of New Mexico. Gila monster. Available at: https:\/\/ehillerman.unm.edu\/1602. Accessed June 18, 2026."},{"key":"10.1016\/j.clindermatol.2026.09.011_bib0008","doi-asserted-by":"crossref","first-page":"3430","DOI":"10.1242\/jeb.004820","article-title":"Metabolic and digestive response to food ingestion in a binge-feeding lizard, the Gila monster (Heloderma suspectum)","volume":"210","author":"Christel","year":"2007","journal-title":"J Exp Biol"},{"key":"10.1016\/j.clindermatol.2026.09.011_bib0009","first-page":"G470","article-title":"Actions of Gila monster venom on dispersed acini from guinea pig pancreas","volume":"242","author":"Raufman","year":"1982","journal-title":"Am J Physiol"},{"key":"10.1016\/j.clindermatol.2026.09.011_bib0010","doi-asserted-by":"crossref","first-page":"1300","DOI":"10.1016\/S0140-6736(87)91194-9","article-title":"Glucagon-like peptide-1 7-36: a physiological incretin in man","volume":"2","author":"Kreymann","year":"1987","journal-title":"Lancet"},{"key":"10.1016\/j.clindermatol.2026.09.011_bib0011","doi-asserted-by":"crossref","first-page":"7402","DOI":"10.1016\/S0021-9258(18)42531-8","article-title":"Isolation and characterization of exendin-4, an exendin-3 analogue, from Heloderma suspectum venom. further evidence for an exendin receptor on dispersed acini from guinea pig pancreas","volume":"267","author":"Eng","year":"1992","journal-title":"J Biol Chem"},{"key":"10.1016\/j.clindermatol.2026.09.011_bib0012","doi-asserted-by":"crossref","first-page":"234","DOI":"10.1038\/s41392-024-01931-z","article-title":"Glucagon-like peptide-1 receptor: mechanisms and advances in therapy","volume":"9","author":"Zheng","year":"2024","journal-title":"Signal Transduct Target Ther"},{"key":"10.1016\/j.clindermatol.2026.09.011_bib0013","doi-asserted-by":"crossref","first-page":"1077","DOI":"10.1056\/NEJMoa2500969","article-title":"Oral semaglutide at a dose of 25 mg in adults with overweight or obesity","volume":"393","author":"Wharton","year":"2025","journal-title":"N Engl J Med"},{"key":"10.1016\/j.clindermatol.2026.09.011_bib0014","unstructured":"Novo Nordisk. Wegovy pill prescriptions surpass 3 million, 1 filled roughly every 5 seconds, bringing GLP-1 therapy to people with obesity previously untreated, while Novo Nordisk unveils new data at ADA 2026. Available at: https:\/\/www.novonordisk.com\/news-and-media\/news-and-ir-materials\/news-details.html?id=916566. Accessed June 10, 2026."},{"key":"10.1016\/j.clindermatol.2026.09.011_bib0015","doi-asserted-by":"crossref","first-page":"743","DOI":"10.1111\/j.1365-2133.2011.10393.x","article-title":"Obesity and the skin","volume":"165","author":"Shipman","year":"2011","journal-title":"Br J Dermatol"},{"key":"10.1016\/j.clindermatol.2026.09.011_bib0016","doi-asserted-by":"crossref","DOI":"10.1002\/ski2.160","article-title":"Obesity-induced immunological effects on the skin","volume":"3","author":"Palanivel","year":"2023","journal-title":"Skin Health Dis"},{"key":"10.1016\/j.clindermatol.2026.09.011_bib0017","doi-asserted-by":"crossref","first-page":"8","DOI":"10.1016\/j.jdin.2025.12.008","article-title":"GLP-1 receptor agonist use in patients with psoriasis or hidradenitis suppurativa","volume":"25","author":"Granovsky","year":"2026","journal-title":"JAAD Int"}],"container-title":["Clinics in Dermatology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0738081X26002373?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0738081X26002373?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,10,29]],"date-time":"2026-10-29T20:52:59Z","timestamp":1793307179000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0738081X26002373"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,9]]},"references-count":15,"alternative-id":["S0738081X26002373"],"URL":"https:\/\/doi.org\/10.1016\/j.clindermatol.2026.09.011","relation":{},"ISSN":["0738-081X"],"issn-type":[{"value":"0738-081X","type":"print"}],"subject":[],"published":{"date-parts":[[2026,9]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"From Gila monster venom to dermatology: The history of glucagon-like peptide-1 receptor agonists","name":"articletitle","label":"Article Title"},{"value":"Clinics in Dermatology","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.clindermatol.2026.09.011","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2026 Elsevier Inc. All rights are reserved, including those for text and data mining, AI training, and similar technologies.","name":"copyright","label":"Copyright"}]}}